S U M M A R Y Levodopa with carbidopa suppressed prolactin release induced by thyrotrophin releasing hormone less effectively in patients with idiopathic Parkinson's disease than in normal subjects. This finding supports the view that the biochemical defect in idiopathic Parkinson's disease extends to the hypothalamus and is not confined to the basal ganglia. Aetiological considerations in Parkinson's disease should encompass a widespread disorder of neurotransmission whose extent merits further investigation.
The therapeutic response to levodopa in Parkinson's disease is associated with dopamine deficiency in the nigro-striatal system.' A separate dopaminergic system with neurones in the hypothalamus but axons terminating in the median eminence2 is closely concerned in the regulation of prolactin release. The purpose of this study was to determine whether the disorder of neurotransmission in idiopathic Parkinson's disease extends to this hypothalamic system or is confined to the basal ganglia. We now report evidence of hypothalamic involvement in untreated patients, shown by the following technique.
Dopamine is a potent inhibitor of prolactin release. Plasma levels are reduced by levodopa and by dopamine agonist drugs in both normal subjects and patients with hyperprolactinaemia. [3] [4] [5] In contrast, the thyrotrophin releasing hormone (TRH) stimulates prolactin release and Refetoff et all' have shown that this response also can be inhibited by pretreatment with levodopa. We therefore stimulated the release of prolactin by TRH in Parkinsonian patients and normal subjects, and have examined the effect of pretreatment with levodopa upon this response. By combining levodopa with a peripheral decarboxylase inhibitor we have ensured that inhibition of prolactin release involved intracerebral decarboxylation of levodopa to dopamine.
Patients and methods
Seven patients with idiopathic Parkinson's disease and seven normal subjects were investigated with their informed consent. Each group comprised four males and three females, ages ranging from 32 to 72 years in the control group (mean 49 4 years) and from 37 to 68 years in the patients (mean 55 7 years). None of the patients had been treated with dopaminergic or anticholinergic drugs. The optimum pre-treatment dose of levodopa combined with a peripheral decarboxylase inhibitor (Sinemet, Hoechst) was determined by measuring the dose-response effect of Sinemet on TRH-induced prolactin release. Figure 1 shows the inhibitory effect of pretreatment with single doses on prolactin release induced by TRH 200 jug intravenously in a normal subject. The dose of levodopa 62 5 mg with carbidopa 6-25 mg was chosen in order to achieve partial suppression of the normal response. This preliminary study also refuted the report by Woolf et al7 that levodopa is incapable of inhibiting prolactin release when combined with a peripheral decarboxylase inhibitor.
Each patient and normal subject received TRH 200 gg intravenously on two occasions with an interval of at least three days. In experiment 1 serum prolactin was measured before and 20 minutes after TRH to determine the normal response. In experiment 2 the procedure was repeated following oral 1012 
